Please assess the completion status of the following clinical trial:

Trial Title: Phase IIB Pilot of Atazanavir + Raltegravir

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Human Immunodeficiency Virus (HIV)-1 positive status~* HIV ribonucleic acid (RNA) level \>=5000 copies/mL~* Antiretroviral treatment-naive~* Absolute Cluster of Differentiation 4 (CD4) cell count meeting 1 of the following criteria:~* \<350 cells/mm\^3~* Screening CD4 \>=350 and \<=500 cells/mm\^3 ONLY if at least 1 of the following conditions apply:~  * Screening HIV RNA level \>100,000 copies/mL, or~ * CD4 decline \>50-100 cells/mm\^3/year, or~ * Age \>=55 years~* Any CD4 cell count, if participant has a history of an acquired immune deficiency syndrome-defining illness~* Medically stable~Exclusion Criteria:~* Screening HIV genotype showing resistance to any component of the study regimen (Atazanavir, Raltegravir, Tenofovir/Emtricitabine)~* Hepatitis B or hepatitis C coinfection~* History of or current cardiac disease~* Electrocardiogram findings:~* PR Interval \>260 msec (severe 1st degree atrioventricular block)~* QRS Interval \>120 msec

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atazanavir + Raltegravir (Type: EXPERIMENTAL): Atazanavir 300 mg twice daily + Raltegravir 400 mg twice daily
- Atazanavir + Ritonavir + Tenofovir /Emtricitabine (Type: ACTIVE_COMPARATOR): Atazanavir, 300 mg once daily, + Ritonavir, 100 mg once daily, + Tenofovir 300 mg/Emtricitabine, 200 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).